Compare XPON & BCDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XPON | BCDA |
|---|---|---|
| Founded | 2016 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electronic Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3M | 14.1M |
| IPO Year | 2022 | 2009 |
| Metric | XPON | BCDA |
|---|---|---|
| Price | $5.19 | $1.10 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $25.00 |
| AVG Volume (30 Days) | ★ 5.2M | 162.2K |
| Earning Date | 05-14-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 94.63 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $9,651,870.00 | $479,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 71.59 | N/A |
| 52 Week Low | $0.26 | $0.75 |
| 52 Week High | $11.79 | $2.27 |
| Indicator | XPON | BCDA |
|---|---|---|
| Relative Strength Index (RSI) | 51.50 | 56.90 |
| Support Level | $0.53 | $0.78 |
| Resistance Level | $11.79 | $1.26 |
| Average True Range (ATR) | 1.42 | 0.06 |
| MACD | -0.24 | -0.00 |
| Stochastic Oscillator | 22.13 | 50.73 |
Expion360 Inc focuses on the design, assembly, manufacturing, and sale of lithium iron phosphate (LiFePO4) batteries and related accessories for RV, marine, and industrial applications. Its high-performance battery solutions are designed for high energy density and a compact footprint, supported by engineering and intellectual property to enhance safety, quality, and performance. The company also engages in product design, development, and collaboration to strengthen customer relationships. It serves dealers, wholesalers, private-label customers, and OEMs, who distribute its products to end consumers. Its segment is Energy Storage (ES), providing lithium-based energy solutions backed by durable materials, optimized internal structures, and responsive customer service.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).